# Professor 6: VEP/PLM expert (strictness=highest)

## Scores
A: 8.0
B: 7.5
C: 7.0
D: 6.0
E: 8.0
F: 7.0
G: 6.5
H: 7.0
I: 9.0
J: 7.5
total: 73.5/100

## Rationale (≤3 sentences each item)
A: The problem is now sharply scoped to region-level, single-position hotspot detection on RNA-virus surface glycoproteins, and the distinction from per-variant VEP benchmarks is repeatedly stated. The motivation is credible because frequency/entropy dominance and the absence of standardized region-level viral hotspot evaluation are real gaps. The deduction is that "hotspot" remains an operational union of several biological concepts rather than a single natural target variable.

B: The related-work section is substantially improved and correctly positions ProteinGym, EVEREST v3, ViroGym, EVEscape, PLANT, antigenic cartography, HyPhy/FUBAR, homoplasy, and cancer hotspot tools as adjacent rather than identical tasks. From a VEP/PLM perspective, the coverage is current and mostly fair, but it still relies on task separation to avoid direct comparison rather than deeply analyzing why per-variant VEP evidence should or should not transfer to region detection. The PLM discussion is weakened by the manuscript's own later admission that Tranception is effectively an ESM-2 proxy for most pathogens.

C: The methodology is ambitious and well documented: 20 scoring formulas, 39 detector variants, MCC primary evaluation, cluster-bootstrap omega-squared, LOPO, Friedman, vaccine-escape audit, and several null/sensitivity analyses. However, Layer A is heterogeneous and single-team curated, DMS exists for only 6/11 pathogens, external escape validation is only 3/11, and the PLM/EVEscape components use substitutes rather than true model-family comparisons. The conservative cell-level omega and label-leakage distinction for EqualWeight are good repairs but do not fully remove ground-truth provenance as a central methodological confound.

D: The raw evaluation grid is large at 8,580 cells, but biologically the active benchmark is only 11 surface proteins from 11 pathogens, with 9--54 positive labels per pathogen and only six DMS-backed pathogens. For VEP/PLM standards, this is a modest panel, especially given claims about pathogen-dependent model choice and adaptive selection. The author's own negative callability result, weak prospective backtest, and 20--30+ pathogen future-work target justify a substantial scale deduction.

E: Interpretation is unusually disciplined: LOPO 0/11 is explicitly called null-consistent, Friedman non-significance is not overclaimed, H3N2 is demoted to self-consistency, SARS-CoV-2 escape is exploratory, and HIV-1 is correctly treated as the primary external anchor. The manuscript also acknowledges winner's curse, residual omega, prospective failure, PLM leakage, and Layer A provenance. Remaining concern: occasional language still makes the practical recommendation table sound more operational than the evidence supports.

F: The contribution is original as a region-level, single-position viral hotspot benchmark with information-source-by-pathogen variance decomposition, not as a new VEP model or PLM method. The strongest novelty is the framing and audit structure, especially separating information source from detector family and quantifying the scoring-pathogen interaction. The deduction is that many technical components are proxies or recombinations of existing scores, and the main biological finding is partly entangled with heterogeneous label definitions.

G: Practical value exists for retrospective prioritization, especially the HIV-1 Layer-A-disjoint escape enrichment and the demonstration that a small candidate set can enrich escape positions. But deployment value is sharply limited: prospective performance is near chance on most pathogens, the abstention rule calls 0/12 folds, adaptive weighting fails, and no live surveillance integration is shown. I would describe the current value as a research triage framework, not a production-ready surveillance method.

H: The dissertation is clear in boundaries, ledgers, and caveat tables, and the reader can usually tell which statistic supports which claim. At the same time, the text is very dense, with many audit waves, parallel panels, and variant-specific EqualWeight definitions that require close tracking. Several sections read like defense addenda rather than a smooth dissertation narrative, which reduces readability despite improving evidentiary precision.

I: Limitation awareness is the strongest aspect of the manuscript. It explicitly discloses Layer A heterogeneity, lack of independent recuration, PLM leakage/proxy collinearity, small-pathogen-panel inference, winner's curse, prospective validation failure, label-provenance non-equivalence, and dual-use concerns. Few dissertations are this explicit about negative gates; the small deduction is only because disclosure is not the same as resolving the limitations.

J: Overall maturity is good: the work has a coherent artifact, reproducibility/provenance claims, multiple sensitivity analyses, and a defensible evidence hierarchy. It is not yet excellent because the central labels are not independently recurred, external validation is narrow, the PLM/VEP component is not strong enough for model-family claims, and the panel is below the scale needed for adaptive selection. As a dissertation, it is mature enough if the claims remain bounded exactly as currently written.

## Critical concerns (if any item < 6)
None. No item falls below 6, but D is close because the biological panel size and validation breadth remain the main constraint.

## Strongest single deduction
D. 실험 규모: 8,580 cells look large computationally, but the biological evidence rests on 11 surface proteins, 6 DMS-backed pathogens, 3 escape-audited pathogens, and 0/12 callable prospective folds; the fix is a 20--30+ pathogen externally curated panel with time-forward validation and independent Layer A recuration.

RESULT_PROF_V6_06: total=73.5/100 min_item=6.0(D) max_item=9.0(I)
